Johnson & Johnson $JNJ Shares Sold by Absher Wealth Management LLC

Key Points

• Absher Wealth Management trimmed its Johnson & Johnson stake by 14.2% in Q4, selling 26,490 shares and retaining 160,607 shares worth about $33.24 million, equal to roughly 3.9% of its portfolio (JNJ is its 8th-largest holding).
• Several large institutions ramped up JNJ positions (notably Capital International +545.6%, Amundi, Marshall Wace), leaving hedge funds and other institutional investors with about 69.55% ownership of the company.
• Company developments include an FDA Priority Review for IMAAVY, the acquisition of Atraverse Medical, a slight quarterly EPS beat and FY2026 guidance of 11.45–11.65 EPS, and a raised quarterly dividend to $1.34 (annualized $5.36; ~2.4% yield).

Absher Wealth Management LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 14.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 160,607 shares of the company's stock after selling 26,490 shares during the quarter. Johnson & Johnson accounts for approximately 3.9% of Absher Wealth Management LLC's investment portfolio, making the stock its 8th biggest holding. Absher Wealth Management LLC's holdings in Johnson & Johnson were worth $33,238,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of JNJ. Capital International Investors grew its stake in shares of Johnson & Johnson by 545.6% during the 3rd quarter. Capital International Investors now owns 3,865,050 shares of the company's stock worth $716,657,000 after purchasing an additional 3,266,354 shares during the period. Amundi grew its position in Johnson & Johnson by 19.3% during the third quarter. Amundi now owns 13,354,936 shares of the company's stock valued at $2,512,719,000 after buying an additional 2,163,838 shares during the period. Marshall Wace LLP grew its position in Johnson & Johnson by 126.3% during the third quarter. Marshall Wace LLP now owns 3,584,162 shares of the company's stock valued at $664,575,000 after buying an additional 2,000,609 shares during the period. Danske Bank A S purchased a new position in Johnson & Johnson in the third quarter valued at $367,467,000. Finally, Wellington Management Group LLP raised its position in shares of Johnson & Johnson by 3.8% in the third quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company's stock worth $4,789,914,000 after acquiring an additional 956,239 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA grants Priority Review for IMAAVY (nipocalimab-aahu) as a potential first approved treatment for warm autoimmune hemolytic anemia — a faster review (≈6 months) raises the chance of an earlier revenue stream and de‑risked late‑stage pipeline value. FDA grants Priority Review for IMAAVY (nipocalimab-aahu)
• Positive Sentiment: JNJ agreed to acquire Atraverse Medical to bolster its left‑heart access and radiofrequency cardiac‑ablation portfolio — a strategic MedTech tuck‑in that can expand procedure addressable market and device pipeline synergies. J&J agrees to acquire Atraverse Medical
• Positive Sentiment: Management says AI is cutting the time to generate drug leads by ~50% — efficiency gains in early discovery could lower R&D cost and accelerate pipeline progression, improving longer‑term margin and pipeline optionality. J&J sees AI halving the time to generate drug development leads
• Positive Sentiment: High‑profile endorsement and dividend appeal — Jim Cramer highlighted JNJ’s strong pipeline and InsiderMonkey/Reddit lists include JNJ among quality dividend picks, supporting interest from income and fundamentals‑focused investors. Jim Cramer Says Johnson & Johnson “Has the Best Pipeline of Potential Blockbusters” Johnson & Johnson – Among the 10 Best Quality Dividend Stocks to Buy According to Reddit
• Neutral Sentiment: Investor outreach: JNJ will present at Bernstein’s Strategic Decisions Conference (May 27) — a chance for management to update strategy and reassure investors, but typically not a catalyst unless material new guidance or announcements are made. Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference
• Neutral Sentiment: Sector headlines (Goldman on UnitedHealth and healthcare ETFs) may be diverting flows across the group — this can mute individual stock moves like JNJ as investors rotate within healthcare. Goldman Sachs Lifts UnitedHealth Target Price
• Neutral Sentiment: JNJ’s reported participation in TrumpRX and other political/PR items could introduce reputational sensitivity for some investors, but so far this is unlikely to materially change fundamentals. Johnson & Johnson Joins TrumpRX

Analysts Set New Price Targets

JNJ has been the topic of a number of analyst reports. Weiss Ratings cut Johnson & Johnson from a "buy (b+)" rating to a "buy (b)" rating in a research report on Friday. Argus upped their price target on Johnson & Johnson from $240.00 to $275.00 and gave the stock a "buy" rating in a report on Thursday, April 16th. Morgan Stanley set a $283.00 price target on Johnson & Johnson in a research report on Wednesday, April 15th. TD Cowen initiated coverage on Johnson & Johnson in a research report on Wednesday, April 8th. They issued a "buy" rating and a $250.00 price objective for the company. Finally, Stifel Nicolaus upped their target price on Johnson & Johnson from $220.00 to $250.00 and gave the stock a "hold" rating in a research note on Wednesday, April 15th. Eighteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus price target of $252.48.

Johnson & Johnson Trading Down 1.0%

Shares of Johnson & Johnson stock opened at $225.23 on Tuesday. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a twelve month low of $146.12 and a twelve month high of $251.71. The firm has a market capitalization of $542.17 billion, a PE ratio of 26.04, a P/E/G ratio of 2.23 and a beta of 0.34. The firm's 50-day moving average price is $239.82 and its 200 day moving average price is $219.11.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The company had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. During the same period in the previous year, the business earned $2.77 EPS. Johnson & Johnson's quarterly revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be issued a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, May 26th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.4%. Johnson & Johnson's payout ratio is currently 60.12%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of the stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at approximately $6,251,310.02. This represents a 4.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares in the company, valued at $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 30,142 shares of company stock valued at $7,360,528 over the last quarter. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.